News | August 26, 2013

Boston Scientific Completes Enrollment In SuperNOVA Trial

Trial evaluates Innova Self-Expanding Stent System

August 26, 2013 — Boston Scientific Corp. has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter clinical trial evaluating the long-term (12-month) safety and effectiveness of the Innova Self-Expanding Stent System (Innova Stent System). This stent system is designed for treating patients with a narrowing or blockage of the arteries above the knee, often associated with peripheral artery disease (PAD).

The study enrolled 299 patients at 51 sites in the United States, Canada, Japan and Europe and is expected to support regulatory submissions in the United States, Canada and Japan.

"Treating vascular lesions in the superficial femoral artery (SFA) and proximal popliteal arteries (PPA) is particularly challenging due to a variety of anatomical factors, including vessel length and tortuosity," said Richard Powell, M.D., section chief, department of vascular surgery, Dartmouth Hitchcock Medical Center, Lebanon, N.H., professor of surgery and radiology at Geisel School of Medicine, and global principal investigator of the SuperNOVA trial. "From my experience in the clinical trial, the Innova Stent System offered the design characteristics required for acute and long term success in these challenging vessels, including radial strength, flexibility, fracture resistance and long stent lengths."

The Innova Stent System consists of a nitinol self-expanding, bare-metal stent loaded on an advanced low-profile delivery system. The stent architecture features a uniform, open-cell structure along the stent body designed for enhanced flexibility, radial strength and fracture resistance and a closed-cell design at each stent end for uniform deployment. The delivery system of the Innova Stent System features a tri-axial delivery catheter with an outer stabilizer sheath engineered to enhance deployment accuracy. The Innova Stent is 6 French compatible and available outside the United States in diameters from 5-8 mm and lengths of 20-200 mm.

More than 27 million people worldwide suffer from PAD, a buildup of plaque that narrows and blocks the arteries, reducing blood flow to the limbs. PAD most commonly occurs in the pelvis and legs, sometimes causing symptoms such as cramping, numbness and pain in the calves or thighs while walking. Left untreated, PAD of the lower extremities can lead to painful wounds on the feet and toes, infections or amputation.

The Innova Stent System received CE mark approval in May 2012. In the United States, the device is investigational and not available for sale.

For more information: www.bostonscientific.com

Related Content

News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices| May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Interrupting Inflammatory Signals Decreases Repeat Artery Blockage
News | Peripheral Arterial Disease (PAD)| May 12, 2017
Peripheral artery disease (PAD) patients who were treated with an anti-inflammatory steroid injected directly into the...
Assessing Heart Disease Risk Within Arm's Reach

This figure demonstrates the histological grading scale that was used in accordance with the American Heart Association (AHA) to assign grades of atherosclerosis. The purpose of this figure is to give criteria and explain why sections were assigned specific grades. Sections are stained in hematoxylin and eosin. Stars indicate the vessel lumen. Horizontal panels represent each grade observed in the study, I-VII (excluding VI). The vertical columns depict the same sections at different magnifications. Image courtesy of Christopher Hoehmann.

News | Cardiac Diagnostics| May 03, 2017
May 3, 2017 — A new study published in...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Arterial Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
First U.S. Patient Treated in DISRUPT PAD III Study of Lithoplasty Technology
News | Peripheral Arterial Disease (PAD)| April 12, 2017
PinnacleHealth CardioVascular Institute last week enrolled the first patient in the United States in a trial assessing...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Overlay Init